2018
DOI: 10.1093/cvr/cvy090
|View full text |Cite
|
Sign up to set email alerts
|

Personalizing therapy for atrial fibrillation: the role of stem cell and in silico disease models

Abstract: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with substantial morbidity. There is considerable inter-patient variability in the pathologic processes that promote AF, and this variability likely has a significant genetic basis. Clinically this is reflected by the observation that anti-arrhythmic drugs and interventional procedures have highly variable efficacy, and this highlights the need for adopting a more efficacious personalized approach. We explore recent advancements i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 109 publications
0
8
0
Order By: Relevance
“…Furthermore, some antiarrhythmic drugs are associated with serious toxicities, including drug-induced long QT syndrome, highlighting the importance of screening platforms for precision medicine. Modeling AF with patient-specific iPSC-aCMs has important implications for drug screening and drug discovery as well as enabling individualized assessments of efficacy and safety that guide clinicians toward personalizing therapy even before administering them to patients ( Barichello et al., 2018 ).…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, some antiarrhythmic drugs are associated with serious toxicities, including drug-induced long QT syndrome, highlighting the importance of screening platforms for precision medicine. Modeling AF with patient-specific iPSC-aCMs has important implications for drug screening and drug discovery as well as enabling individualized assessments of efficacy and safety that guide clinicians toward personalizing therapy even before administering them to patients ( Barichello et al., 2018 ).…”
Section: Discussionmentioning
confidence: 99%
“…At the same time, these cells have their own experimental limitations. For example, the developmental maturity of in vitro differentiated hiPSC-CMs remains a major hurdle, as they do not accurately represent the electrophysiological properties of native atrial cardiomyocytes [ 169 ]. hiPSC-CMs have been observed to have relatively depolarized resting membrane potentials during phase 4 spontaneous depolarization, decreased maximum upstroke velocity, and decreased conduction velocity [ 170 ].…”
Section: Challenges Of Psc Modeling and Translational Aspectsmentioning
confidence: 99%
“…There are other methods to advance our knowledge. Since the last decade, preclinical studies involving human induced pluripotent stem cells derived cardiomyocytes have shown promising role in modelling various cardiac diseases including AF and as a potential platform for drug development ( 44 , 45 ). In Hyperthyroidism with AF in children, given the paucity of studies and patient population, future research with human induced pluripotent stem cells-derived cardiomyocytes or tissue engineering are plausible tools to provide important insight into the mechanism of AF in hyperthyroidism and to develop specific management strategies.…”
Section: Discussionmentioning
confidence: 99%